| Name | Title | Contact Details |
|---|
CycleCast makes studio-quality indoor cycling more accessible than ever by delivering hit music and motivational instructors straight to your iPhone. CycleCast works with any indoor bike and brings the energy, intensity, and community of indoor cycling...
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Alamo Home Care Inc is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OPMEDIC Group Inc. is a Outremont, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Counseling Service of Addison County (CSAC) is a local community mental health center located in Middlebury, Vermont. Since 1959, CSAC has been an integral part of the Addison County community. The Counseling Service offers a wide range of professional mental health and developmental services designed to meet the needs of those seeking help. We are able to provide a multi-disciplinary approach that draws on the expertise of our staff, which includes persons trained in developmental services, substance abuse treatment, psychiatry, psychology, mental health counseling, social work, family therapy, and child therapy. Our goal is to help people live more productive lives in their communities. The following Mission Statement and Values were adopted by the CSAC Board of Directors at their October 9th, 1997 Board meeting. The Mission Statement and Values are the result of several staff and community meetings, where input was gathered. The Counseling Service of Addison County is committed to promoting stable and safe communities by helping people live emotionally healthy and satisfying lives. We strive to provide the best mental health, substance abuse, and developmental services to improve the quality of life for all community members. We work collaboratively with community organizations to help individuals and families achieve maximum wellness.